Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab Maintenance in First-line MCL (LYMA)
NCT00921414Phase 3Completed
- Sponsor
- French Innovative Leukemia Organisation
- Start
- Sep 2008
- Primary completion
- Sep 2008
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in mantle cell lymphoma (MCL) comparing Observation with Rituximab Maintenance (2 arms). Primary endpoint: Event-Free Survival at 4 years. Started Sep 2008; status: completed.
02
Drugs
rituximab
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT00921414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00921414.